ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings Inc (CERO)

2,48
0,13
(5,53%)
À la fermeture: 25 Janvier 10:00PM
2,3201
-0,1599
( -6,45% )
Après les heures de négociation: 12:27AM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
2,3201
Prix Achat
2,32
Prix Vente
2,45
Volume échangé
2 787 832
2,2113 Fourchette du Jour 2,72
2,11 Plage de 52 semaines 1 238,00
Clôture Veille
2,35
Ouverture
2,30
Dernière Transaction
1227
@
2.3201
(formt)
Dernière heure de transaction
00:27:05
Volume moyen (3 m)
102 283 603
Volume financier
US$ 6 704 383
VWAP
2,4049

CERO Dernières nouvelles

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance...

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) --   CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next...

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next...

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an...

CERo Therapeutics, Inc. Provides Corporate Update

Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation...

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes SOUTH SAN FRANCISCO, Calif., Sept. 25, 2024 (GLOBE...

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

Company anticipates initial human trials to focus on AML upon IND clearance SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) --  CERo...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.1299-5.302040816332.453.492.112123762.30349698CS
4-3.8399-62.3360389616.1610.252.11793244315.30945219CS
12-5.1899-69.10652463387.5144.772.1110228360317.71035914CS
26-16.9099-87.934997399919.2344.772.114985383517.17065411CS
52-522.6799-99.558076190552512382.112787492120.46747683CS
156-522.6799-99.558076190552512382.112787492120.46747683CS
260-522.6799-99.558076190552512382.112787492120.46747683CS

CERO - Frequently Asked Questions (FAQ)

What is the current CERo Therapeutics share price?
The current share price of CERo Therapeutics is US$ 2,3201
What is the 1 year trading range for CERo Therapeutics share price?
CERo Therapeutics has traded in the range of US$ 2,11 to US$ 1 238,00 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
HWHHWH International Inc
US$ 0,443
(53,98%)
3,95M
TCTMTCTM Kids IT Education Inc
US$ 0,4087
(25,41%)
6,74M
TVGNTevogen Bio Holdings Inc
US$ 1,69
(25,19%)
2,95M
LGTYLogility Supply Chain Solutions Inc
US$ 13,77
(21,64%)
969
HUBCWHub Cyber Security Ltd
US$ 0,03
(17,65%)
600
ACONAclarion Inc
US$ 0,0434
(-20,95%)
34,7M
MVSTMicrovast Holdings Inc
US$ 1,87
(-14,22%)
1,76M
DGNXDiginex Ltd
US$ 7,6101
(-10,99%)
10,46k
ATXIAvenue Therapeutics Inc
US$ 1,7101
(-9,52%)
36,87k
CDTConduit Pharmaceuticals Inc
US$ 0,0412
(-8,85%)
669,05k
ACONAclarion Inc
US$ 0,0434
(-20,95%)
34,7M
MULNMullen Automotive Inc
US$ 0,5154
(16,95%)
20,9M
RIMEAlgorhythm Holdings Inc
US$ 0,036
(-4,76%)
9,99M
TCTMTCTM Kids IT Education Inc
US$ 0,4087
(25,41%)
6,74M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,3928
(2,53%)
4,9M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock